FDA Approves Krystal Biotech’s VYJUVEK™: First Redosable Skin-disorder Gene Therapy
Krystal Biotech, Inc., a Pennsylvania-headquartered biotech company specialising in genetic medicines for rare diseases, announced on Friday that the US
Read moreKrystal Biotech, Inc., a Pennsylvania-headquartered biotech company specialising in genetic medicines for rare diseases, announced on Friday that the US
Read moreCoya Therapeutics’ investigational low-dose interleukin-2 (IL-2) for subcutaneous administration, COYA 301, has been found to increase Treg function and halt
Read moreAccording to a recent UK population-based study published in The Lancet, approximately one in ten individuals are now affected by
Read moreChiesi Global Rare Diseases and Protalix BioTherapeutics, Inc. have received marketing authorization from the European Commission (EC) for their drug,
Read moreJanssen has received its first worldwide approval for AKEEGA® (Niraparib and Abiraterone Acetate Dual Action Tablet) as EC Authorized treatment
Read moreGSK has entered into an agreement to acquire BELLUS Health, a Canadian late-stage biopharmaceutical company, for a total consideration of
Read morePlasma protein binding is a phenomenon where drugs bind to proteins in the blood, thereby reducing the concentration of free,
Read moreJapanese multinational pharmaceutical company Shionogi & Co., Ltd,. announced at the beginning of April that the U.S. FDA has granted
Read moreInflaRx N.V., a biopharmaceutical company in the clinical stage of developing anti-inflammatory therapeutics that target the complement system, has announced
Read moreThe potential achievements of personalised medicine and AI in pharma are vast and varied. But moving closer to transforming pharmaceuticals
Read more